ArticleWorld journal of surgical oncology2025
Ferroptosis-related differential gene expression and immune correlates in luminal a subtype breast cancer: a prognostic model approach.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis in Breast Cancer: Molecular Insights and Therapeutic Strategies.Frontiers in bioscience (Landmark edition) · 2026Review
- The predictive value of platelet-to-lymphocyte ratio and lymphocyte count in recurrent small intestinal hemorrhage: a retrospective cohort study.BMC gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify reliable prognostic biomarkers and novel therapeutic targets for Luminal A subtype breast cancer, a prevalent subtype with unmet needs in overcoming endocrine resistance. Given the rising global incidence of breast cancer, high recurrence/drug resistance rates in Luminal A patients, and limited research on ferroptosis in this subtype, we analyzed 421 Luminal A subtype breast cancer samples and 113 adjacent normal tissues from The Cancer Genome Atlas (TCGA) database. Differential expression analysis (log₂|fold change|>1, p < 0.05) and univariate Cox regression for overall survival (OS) identified 12 ferroptosis-related differentially expressed genes (DEGs) with prognostic value. Using Lasso-Cox regression (10-fold cross-validation to avoid overfitting), we further optimized these into a 9-gene prognostic model. Univariate and multivariate Cox regression confirmed the model-derived risk score as an independent prognostic factor for OS (HR = 3.896, 95% CI = 2.195-6.916, p < 0.001) in TCGA. External validation in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort (584 Luminal A samples) demonstrated consistent prognostic performance (log-rank p < 0.001), confirming the model's robustness. Functional enrichment analysis showed these genes were enriched in ferroptosis-related pathways, including "lipid biosynthetic process"(Gene Ontology) and "FoxO signaling pathway" (Kyoto Encyclopedia of Genes and Genomes). Single-sample gene set enrichment analysis revealed high-risk groups had increased infiltration of immunosuppressive cells (mast cells, neutrophils, regulatory T cells) and elevated type II interferon response, while low-risk groups had higher type I interferon response. Spearman's correlation analysis identified ENPP2 as a key mediator of immune escape, with a strong positive correlation with PD-1 (r = 0.46, p = 8.7e-24). This 9-gene ferroptosis-related model provides a robust tool for OS prediction in Luminal A subtype breast cancer and highlights ENPP2 as a potential target for combining ferroptosis inducers with immune checkpoint inhibitors-offering a novel strategy for endocrine-resistant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.